Arsenic trioxide reduces the expression of E2F1, cyclin E, and phosphorylation of PI3K signaling molecules in acute leukemia cells.
Arsenic trioxide (ATO) has been used for the treatment of acute promyelocytic leukemia (APL). Although ATO modulates cell cycle progression and apoptosis in APL cells, its exact mechanism of action remains elusive. In this research, we investigated its effects on E2F1, cyclin E, p53, pRb, and PI3K signaling molecules by western blotting, immunocytochemistry and/or confocal imaging. We found that ATO inhibited the proliferation of APL cells through down-regulation of E2F1 and cyclin E expression, and stimulation of pRb. It also reduced the interaction of pRb and E2F1with binding to the E2F1 promoter, by stimulating pRb association. ATO also effected the phosphorylation of pRb at S608 and T373 residues and association of E2F1, pRb, and p53, simultaneously. However, in p53-knockdown NB4 cells, ATO did not significantly reduce E2F1 and cyclin E expression. Our findings demonstrate that ATO inhibits APL cell growth through reduced expression of E2F1, cyclin E, and stimulation of pRb. It also effected both interaction and association of E2F1, pRb, and p53 by phosphorylation of pRb at T373 and S608 residues and reduced phosphorylation of PI3K signaling molecules. This novel mode of action of ATO in APL cells may be useful for designing new APL drugs.
['Kumar|Sanjay|S|', 'Tchounwou|Paul B|PB|https://orcid.org/0000-0002-3407-6674']
D000970:Antineoplastic Agents D017209:Apoptosis D000077237:Arsenic Trioxide D001152:Arsenicals D045744:Cell Line, Tumor D019927:Cyclin E D050687:E2F1 Transcription Factor D006801:Humans D015473:Leukemia, Promyelocytic, Acute D010087:Oxides D019869:Phosphatidylinositol 3-Kinases D010766:Phosphorylation
arsenic trioxide E2F1 PI3K APL P53 pRb